{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:07:40Z","timestamp":1775488060001,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"abstract":"<jats:sec>\n                    <jats:title>\u00a0<\/jats:title>\n                    <jats:p>\n                      Cardiac amyloidosis (CA) frequently coexists with atrial fibrillation (AF), but the extent and impact of this relationship remain unclear. This study investigates the prevalence of AF in CA, compares clinical characteristics between amyloid light-chain (AL)-CA and amyloid transthyretin (ATTR)-CA, and assesses the implications for treatment strategies. We conducted a retrospective analysis of 108 patients with confirmed CA, categorizing them into 2 groups: 51 with AF and 57 with sinus rhythm (SR). We compared demographic, clinical, and echocardiographic data, as well as treatment modalities and outcomes between AL-CA and ATTR-CA subgroups. AF was present in 47% of the cohort, with a notably higher prevalence in wild-type ATTR-CA (80%) compared to AL-CA (33%). Patients with AF were older (73.8\u2005\u00b1\u20058.5 years) than those with SR (67.7\u2005\u00b1\u200510.6 years,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001) and had more severe heart failure symptoms, comorbidities, and echocardiographic abnormalities, including reduced left ventricular ejection fraction (LVEF; 47% vs 53%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.003) and higher pulmonary artery pressures (41\u2005\u00b1\u200511\u2009mm Hg vs 35\u2005\u00b1\u200517\u2009mm Hg,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.02). Logistic regression identified BMI (OR 1.2, 95% CI: 1.05\u20131.57,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.02) and eGFR (OR 0.91, 95% CI: 0.92\u20130.99,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.04) as independent predictors of AF. CHA2DS2-VASc scores were higher in ATTR-CA patients (4.5\u2005\u00b1\u20051.2) compared to AL-CA (2.4\u2005\u00b1\u20051.1,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001). Despite a high rate of anticoagulation (78%), ischemic stroke or TIA incidence was low at 6% over 12 months. AF is highly prevalent in CA, particularly in ATTR-CA, and is associated with more severe clinical manifestations. The findings highlight the necessity for systematic AF screening and tailored management strategies in CA patients. Prospective, randomized studies are essential to establish optimal AF treatment protocols in this population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046522","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:00:17Z","timestamp":1775232017000},"page":"e46522","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes and predictors of atrial fibrillation in cardiac amyloidosis"],"prefix":"10.1097","volume":"105","author":[{"given":"Wajeeh ur","family":"Rehman","sequence":"first","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javaria","family":"Zahir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Sulayman","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadiqa","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Osama","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waheed","family":"Akhtar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahanzeb","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3310-5442","authenticated-orcid":false,"given":"Abida","family":"Parveen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Failure"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis.","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Hear Fail"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis.","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement.","volume":"71","author":"Scully","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release.","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role.","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Failure"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis.","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis.","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis.","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13506129.2020.1798922","article-title":"Arterial thromboembolic events in cardiac amyloidosis: a look beyond atrial fibrillation.","volume":"28","author":"Cappelli","year":"2021","journal-title":"Amyloid"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/CIRCULATIONAHA.120.052136","article-title":"Prevalence of atrial fibrillation and thromboembolic risk in wild-type transthyretin amyloid cardiomyopathy.","volume":"143","author":"Bukhari","year":"2021","journal-title":"Circulation"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ehf2.12602","article-title":"Stroke risk and atrial mechanical dysfunction in cardiac amyloidosis.","volume":"7","author":"Ballantyne","year":"2020","journal-title":"ESC heart failure"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis.","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome.","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis.","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"R22-20260406","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, clinical outcomes.","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ Res"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ehj.2004.04.007","article-title":"Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation.","volume":"25","author":"Leone","year":"2004","journal-title":"Eur Heart J"},{"key":"R24-20260406","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","article-title":"Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation.","volume":"106","author":"R\u00f6cken","year":"2002","journal-title":"Circulation"},{"key":"R25-20260406","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/13506129.2018.1450241","article-title":"Response: atrial impairment in transthyretin cardiac amyloidosis: an early marker of cardiac involvement and a prognostic factor.","volume":"25","author":"Henein","year":"2018","journal-title":"Amyloid"},{"key":"R26-20260406","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jacc.2019.02.078","article-title":"Predicting the unpredictable: how to score the risk of stroke in cardiac amyloidosis?","volume":"73","author":"Russo","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R27-20260406","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1016\/j.jacc.2019.04.005","article-title":"Reply: cardiac amyloidosis, atrial arrhythmias, thrombus, and stroke: a vexing problem.","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R28-20260406","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases.","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:00:40Z","timestamp":1775484040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":28,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046522","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2025-07-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}